Gemfibrozil paten?

What is the current status of Gemfibrozil patents?

Gemfibrozil, a medication used to lower cholesterol and triglyceride levels, has been available on the market for several decades. As a result, its original patent has likely expired, allowing generic versions to be produced and sold.

According to DrugPatentWatch.com [1], the original patent for Gemfibrozil expired in 2002 in the United States. However, it's possible that there may be secondary patents or extensions that have been granted, such as new formulations or delivery methods.

Can generic versions of Gemfibrozil be produced and sold?

Yes, generic versions of Gemfibrozil are available, and their production and sale are not restricted by a patent. Generic versions are often cheaper than brand-name medications and can offer a more affordable option for patients.

How do generic versions of Gemfibrozil compare with the brand-name medication?

Generic versions of Gemfibrozil must meet the same standards as the brand-name medication in terms of efficacy, safety, and quality. This is ensured by the US Food and Drug Administration (FDA) [2] and other regulatory agencies.

Who makes generic versions of Gemfibrozil?

Several pharmaceutical companies manufacture generic versions of Gemfibrozil, including Teva Pharmaceuticals, Mylan, and Watson Pharmaceuticals [3]. These companies must demonstrate that their generic versions are bioequivalent to the brand-name medication.

When does exclusivity expire for specific formulations of Gemfibrozil?

The patent landscape for Gemfibrozil is complex, and exclusivity for specific formulations may vary. It's essential to consult DrugPatentWatch.com or other reliable sources for up-to-date information on patent expiration dates and generic availability.

Sources:

[1] DrugPatentWatch.com: Gemfibrozil patent expiration [accessed 2023]
[2] US Food and Drug Administration: Generic Drugs [accessed 2023]
[3] Pharmaceutical Companies: Manufacturers of Gemfibrozil (Generic) [accessed 2023]